Best Peptides for Sleep in 2026
For each peptide that has been studied in relation to sleep, this page reports the human trials behind it: who was enrolled, what was measured, what the paper found. Every citation was retrieved through NCBI E-utilities on 9 August 2026. Most of these are single-night sleep-laboratory experiments measuring the sleep EEG after injections, so the population column is where a result in young men and a result in elderly women pull apart. Persistent insomnia is a clinical assessment, and nothing here is a treatment plan.
355
Minutes of non-REM sleep in 10 young men after nocturnal ghrelin, versus 336 on placebo (PMID 18329818)
48
Adults in the GHRH recovery-night trial after 40 hours awake (PMID 16912060)
18
Chronic insomniacs in the DSIP sleep-laboratory study (PMID 3792404)
The Studies
One row per study, not one per compound. A peptide studied in three separate trials gets three rows, because those papers asked different questions in different people. The dose each trial used sits in the block below the table, not in these cells.
| Compound | Population (n) | What was measured | Result | Design | PMID |
|---|---|---|---|---|---|
| DSIP, delta sleep-inducing peptide | 18 chronic psychophysiological insomniacs in two age bands, 29 to 59 and 60 to 83 | Polysomnographic sleep variables during a dosing week and a follow-up week | Sleep reached laboratory-normal values by the end of dosing in the middle-aged band and by the end of follow-up in the older band; the size of the change tracked baseline severity | Open sleep-laboratory administration study, intravenous, one week plus follow-up | 3792404 |
| DSIP, measured rather than administered | 15 drug-free men with a DSM-IIIR diagnosis of schizophrenia | Cerebrospinal-fluid DSIP-like immunoreactivity against the prior night sleep stages | Immunoreactivity correlated with stage 3 sleep (P = 0.05) and with combined stage 3 and 4 sleep in the first NREM period (P = 0.02) | Cross-sectional lumbar-puncture and polysomnography study, three nights | 1475566 |
| GHRH, growth hormone-releasing hormone | Healthy young women, studied on days 4 to 6 of the menstrual cycle; n not stated in the abstract | Sleep EEG stages after two intravenous dose levels versus placebo | REM sleep fell in the first half of the night at the lower dose; stage 4 sleep fell at the higher dose, both against placebo | Randomised placebo-controlled crossover, consecutive nights | 17850984 |
| GHRH, on a recovery night | 48 healthy women and men aged 19 to 67, after 40 hours of sleep deprivation | NREM sleep and wakefulness on the recovery night | NREM sleep rose and wakefulness fell more after GHRH than after placebo; no sex difference in this change | Randomised injections on the recovery night, placebo comparator | 16912060 |
| GHRH, sex-stratified | 35 patients with depression and 40 matched controls, aged 19 to 76 | NREM and stage 2 sleep after pulsatile intravenous administration | GHRH raised NREM and stage 2 sleep in men and lowered them in women, regardless of diagnosis (F = 6.0 and 7.1, P < 0.05) | Pulsatile administration against baseline nights, sex-stratified | 11382894 |
| Ghrelin | 10 healthy young men, mean age 25.7 | Non-REM and REM minutes across the night after four nocturnal injections | Non-REM sleep 355.3 minutes versus 336.3 on placebo (P < 0.05); REM sleep fell to 74.2 to 84.3 versus 100.9 | Single-blind randomised placebo-controlled crossover, polysomnography | 18329818 |
| Ghrelin, in later life | 10 elderly men and 10 elderly postmenopausal women, mean age 63 to 64 | Slow-wave, stage 2, non-REM and REM minutes after four injections | In men, slow-wave sleep 44.3 versus 33.4 minutes and non-REM 318.2 versus 272.6 minutes on placebo; in women no sleep change was seen | Single-blind randomised placebo-controlled crossover, polysomnography | 19647945 |
| Galanin | Healthy young men, 10 at the lower dose and 8 at the higher dose | REM sleep by cycle and EEG spectral power after hourly intravenous boluses | REM sleep rose in the third sleep cycle at both doses; delta and theta EEG power rose across the night at the lower dose only | Two-dose intravenous administration, sleep EEG | 10367988 |
| Neuropeptide Y | Young men, 9 at the lower dose and 11 at the higher dose | Sleep period time, stage 2, sleep latency and time awake after four injections | Sleep period time and stage 2 rose (F = 12.8 and 5.4, P < 0.05); sleep latency and time awake fell (F = 4.9 and 4.4, P < 0.05) against saline | Two-dose placebo-controlled intravenous administration, sleep EEG | 10818263 |
| Somatostatin, SRIF-14 | Healthy elderly controls aged 60 to 73, mean age 67.4; n not stated in the abstract | Total sleep time, REM sleep and wakefulness in the first sleep cycle after hourly injections | Total sleep time and REM sleep fell and time awake in the first cycle rose, against placebo | Placebo-controlled intravenous administration, sleep EEG | 9109105 |
| Octreotide, a somatostatin analogue | 7 young male controls, mean age 22.3 | Stage 4 sleep, REM density, intermittent wakefulness and sigma EEG power after a single subcutaneous dose | Stage 4 fell across the night, REM density fell in the first half, intermittent wakefulness rose in the second half, and sigma power fell, against placebo | Placebo-controlled single-dose administration, sleep EEG | 12955096 |
| Octreotide, in rats | Adult rats given single and repeated subcutaneous doses at three levels | Non-REM, REM and EEG slow-wave activity recorded over 23 hours | The two higher doses suppressed non-REM sleep for one hour; five days of repeated dosing lowered non-REM time and intensity; REM was slightly promoted | Rodent administration study | 9362315 |
The Regimens Administered
The figures each trial used, kept out of the table cells and gathered here with the paper that reported them.
DSIP 30 nmol per kg intravenously, six times over a week (PMID 3792404). GHRH 4 x 25 or 4 x 50 micrograms intravenously at hourly intervals (PMID 17850984); 4 x 50 micrograms in the sex-stratified study (PMID 11382894). Ghrelin 50 micrograms per injection, four nocturnal injections in the elderly study (PMID 19647945). Galanin 4 x 50 or 4 x 150 micrograms intravenously (PMID 10367988). Neuropeptide Y 4 x 50 or 4 x 100 micrograms intravenously (PMID 10818263). Somatostatin SRIF-14 50 micrograms hourly, four doses (PMID 9109105). Octreotide 0.1 mg subcutaneously, single dose (PMID 12955096).
Disclaimer: these are the amounts given inside each experiment, reported so the studies can be read accurately. They are not recommendations, not a titration schedule, and every one was administered under medical supervision in a research setting.
The GHRH And Ghrelin Nights
Much of the sleep-EEG data here comes from one group of neuroendocrine experiments that injected a peptide before and during sleep and recorded polysomnography. In 10 healthy young men, nocturnal ghrelin was followed by more non-REM sleep, 355.3 against 336.3 minutes on placebo, and less REM (PMID 18329818). The same design in later life split by sex: elderly men gained slow-wave and non-REM sleep, elderly women showed no sleep change (PMID 19647945). GHRH ran in parallel, and its direction depended on who received it. On a recovery night after 40 hours awake, 48 adults slept more after GHRH than after placebo (PMID 16912060), and in a sex-stratified study GHRH raised NREM and stage 2 sleep in men while lowering them in women (PMID 11382894). In menstrual-cycle-matched young women studied on their own, GHRH reduced REM and stage 4 sleep (PMID 17850984). These are physiology experiments, not registered treatments; the compound background sits on the CJC-1295 page and the tesamorelin page, both GHRH-based, and the wider category on the growth hormone peptides guide.
DSIP, Named For Delta Sleep
Delta sleep-inducing peptide carries its finding in its name, which records where it was first isolated rather than a settled effect in people. The human record on this page is two small studies. An open sleep-laboratory study gave DSIP to 18 chronic psychophysiological insomniacs across a dosing week and a follow-up week, and reported that polysomnographic sleep moved toward laboratory-normal values, with the size of the shift tracking how disturbed each person started (PMID 3792404). A separate cross-sectional study measured cerebrospinal-fluid DSIP-like immunoreactivity in 15 drug-free men with schizophrenia and found it correlated with stage 3 sleep and with combined stage 3 and 4 sleep in the first NREM period (PMID 1475566). One administered the peptide, the other only measured it, and both describe delta and slow-wave sleep. Compound-level background sits on the DSIP page, and what to check before buying any vial on the COA verification guide.
Galanin And Neuropeptide Y
Two more neuropeptides were injected into healthy young men on the same sleep-EEG rig. Galanin raised REM sleep in the third sleep cycle at both doses tested, and lifted delta and theta EEG power across the night at the lower dose (PMID 10367988). Neuropeptide Y shortened sleep latency and time awake and raised sleep period time and stage 2 sleep against saline (PMID 10818263), alongside a fall in overnight ACTH and cortisol, which is the axis the authors were probing. Both are single-night experiments in young men, so the numbers describe that group and that night. Sleep hygiene levers a person can actually reach sit on the magnesium for sleep guide, calming the stress axis on the cortisol guide, and the anxiety overlap on the anxiety supplements guide.
Somatostatin In The Other Direction
Not every peptide that moves sleep moves it toward more of it, and reading this table honestly means keeping the rows that point the other way. Somatostatin, the natural counterweight to GHRH on growth hormone release, shortened total sleep time and REM sleep and added wakefulness to the first cycle when given to healthy elderly controls (PMID 9109105). Its long-acting analogue octreotide cut stage 4 sleep and sigma EEG power in young men (PMID 12955096), and in rats repeated dosing lowered non-REM time and intensity while slightly promoting REM (PMID 9362315). The hormonal picture these sit inside is on the hormones guide, and the peptides sold as medicines in Vietnam on the therapeutic peptides guide.
How These Records Were Found
Each line states a query, an index and a date. A search result describes what a string matched in one database on one day, and nothing beyond that.
- "delta sleep-inducing peptide" AND sleep in PubMed on 9 August 2026 returned 518 records.
- "delta sleep-inducing peptide" AND randomized controlled trial[pt] in PubMed on 9 August 2026 returned 6 records; the publication-type tag is the boundary of that count.
- ghrelin AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 352 records, among them PMID 18329818 and PMID 19647945.
- "growth hormone-releasing hormone" AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 160 records, among them PMID 17850984, PMID 16912060 and PMID 11382894.
- galanin AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 43 records, among them PMID 10367988.
- "neuropeptide Y" AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 93 records, among them PMID 10818263.
- somatostatin AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 202 records, with PMID 9109105 and PMID 12955096 inside it.
- selank AND sleep in PubMed on 9 August 2026 returned 3 records.
- (epitalon OR epithalamin) AND sleep in PubMed on 9 August 2026 returned 2 records.
- (BPC 157 OR "thymosin beta 4") AND sleep AND humans[mesh] in PubMed on 9 August 2026 returned 2 records. A compound name bounds a search, so names, synonyms and MeSH entry terms were tried where known; delta sleep-inducing peptide is indexed under the MeSH term DSIP.
Frequently Asked Questions
Which peptide should someone use for sleep?+
This page does not rank them. It reports what each cited trial enrolled, what it measured and what it found, so a non-REM minute count in 10 young men and a cerebrospinal-fluid correlation in 15 men with schizophrenia can be told apart. Read the population column first: a result recorded in elderly men is a result in elderly men, not a result in everyone.
Do these peptides work the same in women and in men?+
The trials above did not find that. Pulsatile GHRH raised NREM and stage 2 sleep in men and lowered them in women in the same study (PMID 11382894), and nocturnal ghrelin changed slow-wave and non-REM sleep in elderly men while leaving elderly women unchanged (PMID 19647945). Sex was a variable that moved the direction of the result, not a detail.
Why does GHRH appear to help sleep in some rows and hurt it in others?+
Because the rows are different studies in different people. In young men and on a recovery night after sleep deprivation, GHRH was associated with more NREM sleep (PMID 16912060). In healthy young women it was associated with less REM and less stage 4 sleep (PMID 17850984). The compound label is the same; the population and the endpoint are what carry the finding.
Are ghrelin, GHRH, galanin and neuropeptide Y available as sleep treatments?+
The studies above are single-night or single-week physiology experiments run under medical supervision inside a sleep laboratory, measuring the sleep EEG after injections. They are not registered insomnia treatments, and none was designed as a course of therapy. Persistent poor sleep is assessed by a doctor, who can look for causes a peptide experiment was never testing.
What does DSIP being named for delta sleep actually mean?+
The name records where it was first isolated, not a proven effect in people. The human record here is an open sleep-laboratory administration study in 18 chronic insomniacs (PMID 3792404) and a cross-sectional study correlating cerebrospinal-fluid DSIP levels with stage 3 and 4 sleep in 15 men (PMID 1475566). Both describe delta and slow-wave sleep, and both are small.
Why is somatostatin in a page about sleep?+
Because two administration studies measured its effect on the sleep EEG and both pointed the other way: somatostatin shortened total sleep and REM in elderly controls (PMID 9109105), and its analogue octreotide cut stage 4 sleep and sigma power in young men (PMID 12955096). A peptide that moves sleep can move it toward less of it, which is part of reading this table honestly.
What should someone take to a doctor after reading this?+
The population and the endpoint, not the compound name. If you buy any peptide, what is in the vial is a separate question from what a trial reported, so read the COA verification guide before anything else. Ongoing insomnia, daytime sleepiness or suspected sleep apnoea are clinical assessments, and any injected substance interacts with the rest of your health.
Research And Sources
Every figure above comes from the record its PMID links to, retrieved through NCBI E-utilities on 9 August 2026. The ghrelin, GHRH, galanin, neuropeptide Y and somatostatin sleep-EEG studies come from a single Munich neuroendocrine group and its collaborators; the minute-level values quoted are the means reported in each abstract. Where a number was not in the abstract it was not published here.
Related Reading
For education only, not medical advice. Every figure here is a research figure reported for comparison, not a recommendation, and every regimen above was administered under medical supervision inside its study. Talk to a doctor before starting, stopping or changing anything, and have persistent insomnia, daytime sleepiness or suspected sleep apnoea assessed clinically.